Nuvation Bio Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing was signed February 28, 2022. Nuvation Bio is a clinical-stage oncology biopharmaceutical company; it has no approved products and has not generated product revenue.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $69.0 million | $32.6 million |
| General and administrative expense | $24.3 million | $10.9 million |
| Total operating expenses | $93.3 million | $43.6 million |
| Net loss | $86.8 million | $41.7 million |
| Net loss per share, basic and diluted | $0.44 | $0.43 |
| Cash used in operating activities | $68.2 million | $36.5 million |
Margins are not meaningful because the company had no revenue. At year-end, cash and cash equivalents were $132.4 million and marketable securities were $633.0 million, totaling $765.4 million in cash, cash equivalents and investments. Total assets were $776.2 million, total liabilities $30.2 million, and stockholders’ equity $746.0 million. The filing reports no debt balance. Management said available funds were expected to support operations for at least 12 months after issuance of the financial statements; that estimate depends on assumptions and spending could be higher.
Cash provided by financing was $625.5 million, primarily from the February 2021 business combination and related financing. Investing activities used $454.7 million, mainly reflecting purchases of marketable securities. Accumulated deficit reached $162.8 million. No off-balance-sheet financing arrangements were reported.
Material changes and notable items
- Net loss more than doubled year over year, while operating cash use rose by $31.7 million. R&D expense increased by $36.4 million, mainly from third-party research and manufacturing costs, personnel, and a $3.8 million stock issuance recorded as in-process R&D expense. G&A expense increased by $13.3 million, including higher personnel, insurance and professional fees.
- The February 2021 merger with Panacea and associated PIPE and forward-purchase financing generated approximately $624.8 million of net cash proceeds reported in financing activities. The transaction was accounted for as a reverse recapitalization.
- Other income included a $4.2 million non-cash gain from a decrease in warrant-liability fair value. This reduced reported net loss but was not operating cash generation.
- Marketable securities had $2.7 million of net unrealized losses recognized in other comprehensive loss during 2021. The company reported no impairment charge for those securities.
- Auditor KPMG gave unqualified opinions on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal controls were effective at year-end.
Business outlook, commentary and risks
The company plans to fund continued drug discovery and clinical development and expects significant expenses and operating losses for the foreseeable future. Management’s stated development plans included expanding NUV-422 studies, initiating NUV-868 clinical development in 2022, filing an IND for NUV-569 by year-end 2022, and nominating clinical candidates from the A2A adenosine-receptor and drug-drug conjugate programs by year-end 2022. These are plans, not assurances of completion or success. The FDA had cleared three NUV-422 INDs by December 2021; NUV-868’s IND was cleared in January 2022, after the reporting period. NUV-422 dose-escalation data were expected in the second half of 2022.
- Clinical and regulatory risk: Candidates are investigational; trial outcomes, safety, enrollment, regulatory approval and commercialization are uncertain. Preclinical findings may not predict clinical benefit.
- Funding and execution: Despite substantial year-end liquidity, continued development is costly; actual spending may exceed estimates and future capital may be required.
- Third-party dependence: The company relies on CROs and single-source manufacturers for research, trials and drug supply, with potential interruption, quality and scale-up risks.
- Other risks: Competition, intellectual-property challenges, healthcare pricing and reimbursement, and possible COVID-19 effects on trials, suppliers and operations could adversely affect results. Management said COVID-19 had not materially affected operations to date, but future effects were uncertain.
- The company had no material legal proceedings pending. It does not expect to pay cash dividends in the foreseeable future.
- The dual-class structure concentrates voting rights in CEO David Hung, including specified director-election rights and approval rights over acquisitions or liquidation.
Important facts for investors to verify
- Whether cash, cash equivalents and marketable securities remain sufficient as clinical and R&D spending grows, and how actual cash burn compares with the operating plan.
- Progress, enrollment, safety findings and reported results for NUV-422 and the planned NUV-868 and NUV-569 programs; distinguish clinical evidence from preclinical claims and forecasts.
- Whether planned IND submissions, trial starts and candidate nominations occur on the timelines described, and whether regulatory agencies impose additional requirements.
- Manufacturing capacity, supply continuity and availability of alternate suppliers for clinical-stage candidates.
- Potential dilution from outstanding options, warrants and equity plans, alongside the governance implications of the dual-class share structure.